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In their pilot study, Rudin et al. describe the safety, feasibility and
toxicity profile of the combination of paclitaxel and G3139
(GenasenseTM), a bcl-2 antisense oligonucleotide, in patients with
chemoresistant small-cell lung cancer (SCLC). Tolerance of
G3139 in these patients was good and further studies are ongoing.
Although ‘proof of principle’ was not the aim of the study, and
because repeated tumor biopsy for the measurement of target
protein expression in tumor cells was not possible, bcl-2 protein
expression was measured in peripheral-blood mononuclear
cells (PBMCs) before and after the administration of G3139. A
decrease in bcl-2 protein in PBMCs may prove sustained bio-
logical activity upon G3139 i.v. infusion, however, it is not an
accurate substitute for bcl-2 expression in tumor cells, and there-
fore, no conclusions should be drawn from these results. We
believe that, when studying antisense activity, analysis of the
tumor cells must remain the gold-standard for target validation as
long as no surrogate markers are available. It is especially neces-
sary to evaluate potential surrogate markers, such as circulating
tumor-specific protein, DNA and mRNA, for clinical studies of
patients with tumors that are not readily accessible.
Another concern arises from the fact that untreated, as well as
chemoresistant, SCLC cells express not only bcl-2 but also
bcl-xL, another potent anti-apoptotic protein, at remarkably high
levels [1]. Furthermore, tumor cells are able to switch expression
from bcl-2 to bcl-xL [2], resulting in sustained tumor cell
survival. In order to adequately address this complication, we
have developed a single ‘bispecific’ antisense oligonucleotide
that simultaneously targets the bcl-2 and bcl-xL mRNA. This
compound has demonstrated inhibition of target protein expres-
sion, as well as potent antitumor efficacy, in preclinical models of
various human tumors in vitro and in vivo [3].
The publication by Rudin et al. is an important step towards
the broad therapeutic use of antisense oligonucleotides against
malignant human tumors; we anticipate new challenges will arise
when more of these promising compounds are carried from the
bench to the clinic.
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